José L. Jiménez

José L. Jiménez

Statistician at Novartis

I am a Statistician at Novartis. Before, I was a Marie Curie fellow in the EU-funded network IDEAS. I was based in Politecnico di Torino and I was working under the supervision of Prof. Mauro Gasparini and under the co-supervision of Prof. Mourad Tighiouart (Cedars-Sinai Medical Center, USA). I have a strong interest and great enthusiasm for methodological research to improve efficiency of the design and analysis of clinical trials. See my Google scholar profile.

Download full CV

Education

PhD in Statistics (2018) – Politecnico di Torino, Italy.

Research Interests

Bayesian methods, phase I-II clinical trials, survival analysis.

Selected Publications in Phase I and Phase I-II Clinical Trial Designs

Articles in refereed journals

  1. Tighiouart, M., Jiménez, J. L., Diniz, M.A. and Rogatko, A. (2022+). Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?. Brazilian Journal of Biometrics. In Press. [arXiv Link]
  2. Jiménez, J. L. and Tighiouart, M. (2022). Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials. Journal of the Royal Statistical Society: Series C (Applied Statistics), 71(5), 1996-2013. [Link]
  3. Jiménez, J. L., Kim, S. and Tighiouart, M. (2020). A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations. Biometrical Journal, 62(5), 1300-1314. [Link + R code]
  4. Jiménez, J. L., Tighiouart, M. and Gasparini, M. (2019). Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents. Biometrical Journal, 61(2), 319-332. [Link]. [Github Respository]

Book Chapters (peer-reviewed)

  1. Jiménez, J. L., Diniz, M.A., Rogatko, A., and Tighiouart, M. (2021). Designs of Early Phase Cancer Trials with Drug Combinations. In Modern Statistical Methods for Health Research (pp. 131-160). Springer, Cham.

Manuscripts under review

  1. Jiménez, J. L. and Zheng, H. A Bayesian adaptive design for dual-agent phase I-II cancer clinical trials combining efficacy data across stages. [arXiv Link] (under review)

Selected Publications in Survival Analysis

Articles in refereed journals

  1. Magirr, D. and Jiménez, J. L.(2022+). Stratified modestly-weighted log-rank tests in settings with an anticipated delayed separation of survival curves. Accepted for Publication in Biometrical Journal. [arXiv Link]
  2. Magirr, D. and Jiménez, J. L. (2022). Design and Analysis of group-sequential clinical trials based on a modestly-weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance. Clinical Trials, 19(2), 201-210. [Link + R code]
  3. Jiménez, J. L. (2022). Quantifying treatment differences in confirmatory trials under non-proportional hazards. Journal of Applied Statistics, 49(2), 466-484. [Link] [Github Respository]
  4. Jiménez, J. L., Niewczas, J., Bore, A. and Burman, C. F. (2021). A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching. Plos One, 16(11): e0259178. [Link + R code]
  5. Jiménez, J. L., Stalbovskaya, V. and Jones, B. (2019). Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects. Pharmaceutical statistics, 18(3), 287-303. [Link].

Latest Presentations

  • [2022] Invited talk at COMPSTAT 2022 Conference, Bologna, Italy
  • [2021] Invited talk at PSI One-Day Meeting: Non-proportional hazards and applications in immuno-oncology, Online.
  • [2021] Contributed talk at ISBA World Meeting, Online.
  • [2019] Invited talk at International Symposium in Biopharmaceutical Statistics, Kyoto, Japan.
  • [2019] Invited talk at Servier’s symposium on Innovative Statistical Methods in Oncology, Paris, France.

Contact

jose_luis dot jimenez at novartis dot com